DCPH News and Press, Deciphera Pharmaceuticals Inc. From 08/13/19

- Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – - Median Progression Free Survival (mPFS) Sustained across All Cohorts - - Additional Phase 1 Results Expected to be Presented at Upcoming Medical Meeting - -...

- INVICTUS Achieved Primary Endpoint, Ripretinib Significantly Improved Progression Free Survival (PFS) Versus Placebo in Patients with Fourth-line and Fourth-line Plus GIST - - Median PFS for Ripretinib of 6.3 Months Versus Placebo of 1.0 Month; Hazard Ratio of 0.15, p<0.0001- ...

Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q2 GAAP EPS of -$0.56 beats by $0.53 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Top-line Data from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Fourth-line and Fourth-line Plus Gastrointestinal Stromal Tumor (GIST) Patients Expected this Month - - Ripretinib Granted Fast Track Designation by the U.S. Food and Drug Administration for Treatment of Pati...

Idea Slides Introduction RET mutations are seen in ~2% of NSCLCs. Currently, there are no FDA-approved treatments for RET-mutated NSCLC. Multi-targeted drugs have been tested in these patients, but without much success. RET-targeted therapies like Blueprint Medicines' ( BPMC ) and L...

Note: This article was first revealed to subscribers to my exclusive marketplace, The Formula , in February when shares of Blueprint were trading < $80. Preface Documents: 10-Q | Company Slides Shares: 48,853,933 | PPS: $100 | Market Cap: $4.8B | Enterprise Value...

Outlook Therapeutics (NASDAQ: OTLK ) initiated with Buy rating and $8 (310% upside) at H.C. Wainwright. Shares up  11%  premarket. More news on: Outlook Therapeutics, Inc., Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the appointment of Susan L. Kelley, M.D. to its Board of Directors. Dr. Kelley will serve as an independent director and mem...

Deals and Financings Vivo Capital, a US-China healthcare investment firm, has raised $1.28 billion for its ninth fund, bringing its assets under management to more than $4.3 billion. Vivo invests in all stages of healthcare companies, from start-up to publicly owned. Founded in 1996, Vivo ...

Deciphera Pharmaceuticals (NASDAQ: DCPH ) inks agreement with Zai Lab (NASDAQ: ZLAB ) to commercialize ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). More news on: Zai Lab Limited, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Read more ...